The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.

Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease

NCT00681226

Peripheral Arterial Disease

COMPLETED PHASE4

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928

Atherosclerosis Coronary Disease Vasculitis

COMPLETED PHASE2

Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol

NCT01362218

Elevated LDL Cholesterol

TERMINATED PHASE2

Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

NCT04298567

Prevention of Atherothrombotic Events Coronary Artery Disease (CAD) Symptomatic Peripheral Artery Disease (Symptomatic PAD)

COMPLETED

Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS

NCT04739384

Acute Coronary Syndrome STEMI NSTEMI +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramipril

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ankle-brachial index of \<0.9 at rest in at least one leg
* History of intermittent claudication (unilateral or bilateral) which was stable for 6 months
* Evidence of superficial femoral artery stenosis or occlusion on duplex scan
* Blood pressure \<=160/90 mmHg
* Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors